Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, develops therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma in the United States. It is developing RASP-201, an orally dosed selective reversible inhibitor of lysine specific demethylase (LSD1), which is a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301. The company was formerly known as Rasna Therapeutics, Inc. and changed its name to Actavia Life Sciences, Inc. in October 2023. Actavia Life Sciences, Inc. was founded in 2013 and is based in New York, New York.
0 transactions — 0 buys and 0 sales reported by Actavia Life Sciences, Inc. executives.
0 institutional funds report a position on RASP in their latest SEC quarterly filing.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Detection of clustered purchases or sales by several executives in the same stock.
Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot marked changes in search interest around the stocks being followed.
Create your watchlist and receive a brief of events affecting your tickers.
This public page only shows a preview. The full analysis of RASP on the Kairos Insider dashboard includes:
Free signup · Pro €19/month or €190/year